- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Citalopram or escitalopram may reduce depression and corticosteroids need in patients with asthma and depression
Citalopram or escitalopram may reduce depressive symptoms and corticosteroids needed in patients with asthma and depression suggests a new study published in the Annals of Allergy, Asthma & Immunology.
Major depressive disorder (MDD) is common in people with asthma. Yet, few studies have examined depression treatment in those with asthma.
A study was done to explore the relationship between antidepressant use, depressive symptoms, and asthma control, pooled data from three randomized trials of either citalopram or escitalopram were assessed.
Linear fixed effects and binary logistic regression analyses were conducted with between-subject covariates including treatment group, (original) study, and demographics. The within-subject effect of visit, as well as a treatment group × visit (between-within) interaction effect, were also evaluated. Analyses were repeated in a high asthma exacerbation subgroup having ≥ 3 oral corticosteroid bursts in the prior 12 months. Outcomes included the Hamilton Rating Scale for Depression (HAM-D17), the 7-item Asthma Control Questionnaire (ACQ), and oral corticosteroid use (yes/no).
Results:
In the pooled sample (n = 255), the antidepressant treatment group demonstrated lower HAM-D17 scores overall (p ≤ .001) and a lower likelihood for oral corticosteroid use (p ≤ .001) relative to the placebo group. In the high exacerbation subgroup (n = 96), treatment group participants had lower overall ACQ (p = .004) and HAM-D17 scores (p ≤ .001), and a lower likelihood of oral corticosteroid use (p = .003), relative to placebo participants. All treatment group interaction effects were non-significant.
Citalopram or escitalopram demonstrated efficacy in reducing depressive symptoms and the need for rescue oral corticosteroids in patients with asthma and MDD. Future work should determine whether SSRIs are effective at improving asthma outcomes in those with asthma who are not depressed.
Reference:
Catherine D. Agarwal, Jayme M. Palka, Alexander J. Gajewski, David A. Khan, E. Sherwood Brown. The Efficacy of Citalopram or Escitalopram in Patients with Asthma and Major Depressive Disorder, Annals of Allergy, Asthma & Immunology, 2023, ISSN 1081-1206,
https://doi.org/10.1016/j.anai.2023.11.004.
(https://www.sciencedirect.com/science/article/pii/S1081120623014011)
Keywords:
Citalopram, escitalopram, reduce, depressive, symptoms, corticosteroids, need, patients, asthma, depression, Annals of Allergy, Asthma & Immunology, Catherine D. Agarwal, Jayme M. Palka, Alexander J. Gajewski, David A. Khan, E. Sherwood Brow
Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751